Zacks: Brokerages Expect argenx SE – (ARGX) Will Announce Earnings of -$0.73 Per Share
Equities analysts expect argenx SE – (NASDAQ:ARGX) to report earnings per share of ($0.73) for the current quarter, Zacks reports. Three analysts have provided estimates for argenx’s earnings, with the highest EPS estimate coming in at ($0.55) and the lowest estimate coming in at ($1.01). The company is scheduled to issue its next quarterly earnings report on Thursday, October 25th.
On average, analysts expect that argenx will report full-year earnings of ($1.95) per share for the current financial year, with EPS estimates ranging from ($2.25) to ($1.64). For the next year, analysts forecast that the firm will post earnings of ($3.38) per share, with EPS estimates ranging from ($5.68) to ($2.03). Zacks Investment Research’s EPS calculations are an average based on a survey of analysts that that provide coverage for argenx.
A number of analysts have recently commented on the stock. Wedbush lifted their price target on shares of argenx from $114.00 to $121.00 and gave the stock a “positive” rating in a research note on Tuesday, September 18th. Evercore ISI began coverage on shares of argenx in a report on Monday, October 15th. They issued an “outperform” rating and a $110.00 price objective on the stock. Piper Jaffray Companies reissued an “overweight” rating and issued a $154.00 price objective on shares of argenx in a report on Monday, September 17th. SunTrust Banks raised their price objective on shares of argenx to $132.00 and gave the stock an “in-line” rating in a report on Tuesday, September 18th. Finally, JMP Securities raised their price objective on shares of argenx to $150.00 and gave the stock an “outperform” rating in a report on Monday, September 17th. One research analyst has rated the stock with a hold rating and nine have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $136.00.
Shares of ARGX stock opened at $105.71 on Thursday. argenx has a 52 week low of $28.83 and a 52 week high of $111.43. The company has a market capitalization of $3.11 billion, a PE ratio of -75.51 and a beta of 1.67.
argenx Company Profile
argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company's lead product candidates include ARGX-113 that completed Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis, immune thrombocytopenia, and pemphigus vulgaris; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome.
Recommended Story: What are no-load funds?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for argenx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenx and related companies with MarketBeat.com's FREE daily email newsletter.